International Authority Media Spotlight! Leadingpharm‑Enabled World’s First Non‑viral DMD Therapy Achieves Major Breakthrough

Recently, Spot Biosystems announced the completion of a US$40 million financing round, with positive results from its world‑first non‑viral full‑length dystrophin delivery therapy in animal models and human patients. This milestone quickly attracted extensive coverage from international authoritative media such as Endpoints News and Business Wire. Notably, the clinical translation of this breakthrough research was deeply participated in and organized by Leadingpharm as the CRO.
 

Related link:抗肌萎缩蛋白水平提升超1000%！新领先助力非病毒基因疗法取得全球首个里程碑突破

Endpoints News coverage
 

Business Wire coverage

 

About Us

Deep Blue Ocean Biopharmaceutical is the clinical CRO sub‑brand of Leadingpharm (stock code 600222), established in 2007. Adhering to the philosophy “End‑to‑End, Top‑Level Design, Being the Full‑Process Partner for New Drug Development,” it provides global pharmaceutical companies with services covering Phase I‑III clinical studies, bioequivalence studies, third‑party auditing, IND application strategy guidance, and medical affairs for biologics, chemical drugs, TCM, medical devices, and cell & gene therapies. It meets the customized clinical research needs of various R&D‑oriented companies and helps clients overcome key bottlenecks before new drug launch.

To date, the company has conducted over 2,000 clinical research projects. In cell & gene therapy and aesthetic medicine, multiple projects have achieved domestic/international first‑in‑human or first‑approved status, filling gaps in China and globally. It also possesses extensive experience and resource accumulation in endocrinology, cardiovascular, oncology, rheumatology & immunology, pediatrics, rare diseases, and neuropsychiatry.

-END-